As long as CXCL16 is found in the BM at high levels (343) and CXCL8, the CXCR1, and CXCR2 ligand is significantly elevated in MM (344, 345), CLL (346), AML, and MDS patients (347), the targeting of CXCL16-CXCR6 and IL8-CXCR2/CXCR1 pathways should be studied in depth for hematologic malignancies. Here, CXCL8 is linked to hematologic disorder.